文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

茚达特罗联合格隆溴铵减轻肺过度充气对COPD患者心室充盈的影响(CLAIM):双盲、随机、交叉、安慰剂对照、单中心试验

Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
PubMed 文献 · Lancet Respir Med · 2018-02-21
一句话结论在COPD伴肺过度充气患者中,茚达特罗-格隆溴铵双支气管扩张剂较安慰剂显著提高左心室舒张末期容积指数,作者支持对伴肺过度充气征象的COPD患者早期使用双支气管扩张。

CLAIM为单中心、双盲、随机、两周期交叉、安慰剂对照试验,纳入62例年龄≥40岁、基线残气量>135%预计值、吸烟史≥10包年、FEV1<80%预计值且支气管舒张后FEV1/FVC<0.7的COPD伴肺过度充气患者。患者1:1随机接受茚达特罗110 μg(马来酸盐)联合格隆溴铵50 μg(溴化物盐)每日一次吸入14天,洗脱14天后予匹配安慰剂14天,或相反顺序。主要终点为按体表面积标化的左心室舒张末期容积指数(MRI测量),在意向治疗人群中,茚达特罗-格隆溴铵组从基线均值55.46 mL/m2(SD 15.89)升至最小二乘均值61.76 mL/m2(95%CI 57.68-65.84),安慰剂组从56.42 mL/m2(13.54)变为56.53 mL/m2(52.43-60.62),最小二乘均值治疗差异5.23 mL/m2(95%CI 3.22-7.25;p<0.0001)。最常见不良事件为咳嗽(9例[15%])和咽喉刺激(7例[12%]),严重不良事件各1例(子宫内膜癌、心肌梗死),均认为与治疗无关,无死亡。

要点

  • 在COPD伴肺过度充气(基线残气量>135%预计值)患者中,茚达特罗110 μg联合格隆溴铵50 μg每日一次吸入14天,左心室舒张末期容积指数最小二乘均值61.76 mL/m2,安慰剂组56.53 mL/m2,治疗差异5.23 mL/m2(95%CI 3.22-7.25;p<0.0001)。
  • 该研究为单中心、双盲、随机、两周期交叉、安慰剂对照试验,62例随机分组并纳入意向治疗分析,60例纳入符合方案分析,57例完成两个治疗期。
  • 最常见不良事件为咳嗽(茚达特罗-格隆溴铵组9例[15%])和咽喉刺激(7例[12%]);安慰剂组最常见为头痛(5例[8%])和上呼吸道感染(4例[7%])。
  • 严重不良事件各1例(茚达特罗-格隆溴铵组子宫内膜癌1例[2%],安慰剂组心肌梗死1例[2%]),均认为与治疗无关;研究期间无死亡。
  • 作者认为,该结果支持对伴肺过度充气征象的COPD患者早期使用双支气管扩张。

适用人群与场景

  • 年龄≥40岁的COPD患者,伴肺过度充气(基线残气量>135%预计值)、吸烟史≥10包年、气流受限(FEV1<80%预计值且支气管舒张后FEV1/FVC<0.7)。
  • 稳定期心血管疾病患者可纳入;心律失常、心力衰竭、不稳定缺血性心脏病或未控制高血压患者不纳入。
  • 研究在德国汉诺威Fraunhofer毒理与实验医学研究所(专科门诊)进行。

诊断标准与关键阈值

  • 肺过度充气定义:基线残气量>135%预计值。
  • 气流受限定义:FEV1<80%预计值且支气管舒张后FEV1/FVC<0.7。

处置流程与药物剂量

  • 茚达特罗110 μg(马来酸盐)联合格隆溴铵50 μg(溴化物盐)每日一次吸入,疗程14天;对照为匹配安慰剂每日一次吸入14天。
  • 两治疗期间设14天洗脱期。
  • 主要终点评估时间:治疗期1第1天(访视4)和第15天(访视5),治疗期2第29天(访视6)和第43天(访视7),以MRI测量左心室舒张末期容积并按体表面积标化。

研究设计与关键结果

  • 研究类型:单中心、双盲、随机、两周期交叉、安慰剂对照试验;2015年5月18日至2017年4月20日随机分配62例 eligible 患者,30例为茚达特罗-格隆溴铵后安慰剂,32例为安慰剂后茚达特罗-格隆溴铵;62例纳入意向治疗分析,2例方案违背后60例纳入符合方案分析,57例完成两个治疗期。
  • 主要终点:茚达特罗-格隆溴铵组左心室舒张末期容积指数从基线均值55.46 mL/m2(SD 15.89)升至最小二乘均值61.76 mL/m2(95%CI 57.68-65.84);安慰剂组从56.42 mL/m2(13.54)变为56.53 mL/m2(52.43-60.62);最小二乘均值治疗差异5.23 mL/m2(95%CI 3.22-7.25;p<0.0001)。
  • 不良事件:茚达特罗-格隆溴铵组最常见为咳嗽(9例[15%] of 59)和咽喉刺激(7例[12%]);安慰剂组最常见为头痛(5例[8%] of 61)和上呼吸道感染(4例[7%])。
  • 严重不良事件:茚达特罗-格隆溴铵组1例(2%,子宫内膜癌),安慰剂组1例(2%,心肌梗死),均认为与治疗无关;无死亡。

证据类型、等级与局限

  • 证据类型:随机、双盲、两周期交叉、安慰剂对照、单中心试验。
  • 作者指出这是首个分析LABA-LAMA联合治疗对COPD伴肺过度充气患者心脏功能影响的研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,结果支持对伴肺过度充气征象的COPD患者早期使用双支气管扩张。
  • 研究纳入稳定期心血管疾病患者,但排除了心律失常、心力衰竭、不稳定缺血性心脏病或未控制高血压患者,上述人群未在本研究中评估。

指南或共识出处

  • CLAIM试验,注册号NCT02442206,发表于Lancet Respiratory Medicine,由Novartis Pharma GmbH资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary hyperinflation in chronic obstructive pulmonary disease (COPD) is associated with reduced biventricular end-diastolic volumes and increased morbidity and mortality. The combination of a long-acting β agonist (LABA) and a muscarinic antagonist (LAMA) is more effective in reducing hyperinflation than LABA-inhaled corticosteroid combination therapy but whether dual bronchodilation improves cardiac function is unknown.

METHODS: We did a double-blind, randomised, two-period crossover, placebo-controlled, single-centre study (CLAIM) at the Fraunhofer Institute of Toxicology and Experimental Medicine (Hannover, Germany), a specialty clinic. Eligible participants were patients aged at least 40 years with COPD, pulmonary hyperinflation (defined by a baseline residual volume >135% of predicted), a smoking history of at least ten pack-years, and airflow limitation (FEV1 <80% predicted and post-bronchodilator FEV1: forced vital capacity <0·7). Patients with stable cardiovascular disease were eligible, but those with arrhythmias, heart failure, unstable ischaemic heart disease, or uncontrolled hypertension were not. We randomly assigned participants (1:1) to either receive a combined inhaled dual bronchodilator containing the LABA indacaterol (110 μg as maleate salt) plus the LAMA glycopyrronium (50 μg as bromide salt) once per day for 14 days, followed by a 14-day washout, then a matched placebo for 14 days, or to receive the same treatments in reverse order. The randomisation was done using lists and was concealed from patients and investigators. The primary endpoint was the effect of indacaterol-glycopyrronium versus placebo on left-ventricular end-diastolic volume measured by MRI done on day 1 (visit 4) and day 15 (visit 5) in treatment period 1 and on day 29 (visit 6) and day 43 (visit 7) in treatment period 2 in the per-protocol population. Left-ventricular end-diastolic volume was indexed to body surface area. Safety was assessed in all participants who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02442206.

FINDINGS: Between May 18, 2015, and April 20, 2017, we randomly assigned 62 eligible participants to treatment; 30 to indacaterol-glycopyrronium followed by placebo and 32 to placebo followed by indacaterol-glycopyrronium. The 62 randomly assigned patients were included in the intent-to-treat analysis. There were two protocol violations and therefore 60 were included in the per-protocol analysis. 57 patients completed both treatment periods. After indacaterol-glycopyrronium treatment, left-ventricular end-diastolic volume increased from a mean 55·46 mL/m2 (SD 15·89) at baseline to a least-squares (LS) mean of 61·76 mL/m2 (95% CI 57·68-65·84), compared with a change from 56·42 mL/m2 at baseline (13·54) to 56·53 mL/m2 (52·43-60·62) after placebo (LS means treatment difference 5·23 mL/m2 [95% CI 3·22 to 7·25; p<0·0001]). The most common adverse events reported with indacaterol-glycopyrronium were cough (in nine patients [15%] of 59) and throat irritation (in seven [12%]). With placebo, the most common adverse events reported were headache (in five patients [8%] of 61) and upper respiratory tract infection (in four [7%]). Two patients had serious adverse events: one (2%) after indacaterol-glycopyrronium (endometrial cancer) and one (2%) after placebo (myocardial infarction); these were not thought to be treatment related. No patients died during the study.

INTERPRETATION: This is the first study to analyse the effect of LABA-LAMA combination therapy on cardiac function in patients with COPD and lung hyperinflation. Dual bronchodilation with indacaterol-glycopyrronium significantly improved cardiac function as measured by left-ventricular end-diastolic volume. The results are important because of the known association of cardiovascular impairment with COPD, and support the early use of dual bronchodilation in patients with COPD who show signs of pulmonary hyperinflation.

FUNDING: Novartis Pharma GmbH.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018. PMID: 29477448. doi:10.1016/S2213-2600(18)30054-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。